ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
5.51
-0.88 (-13.71%)
At close: Aug 20, 2026, 4:00 PM EDT
5.61
+0.11 (1.91%)
After-hours: Aug 20, 2026, 4:02 PM EDT
ARS Pharmaceuticals Employees
As of March 31, 2026, ARS Pharmaceuticals had 159 total employees, including 154 full-time and 5 part-time employees. The number of employees decreased by 4 or -2.45% since the number was last reported on December 31, 2025.
Employees
159
Change
-4
Growth
-2.45%
Revenue / Employee
$735,390
Profits / Employee
-$1,354,918
Market Cap
548.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 159 | -4 | -2.45% | 154 | 5 |
| Dec 31, 2025 | 163 | 3 | 1.88% | 158 | 5 |
| Dec 31, 2024 | 160 | 134 | 515.38% | 155 | 5 |
| Dec 31, 2023 | 26 | 6 | 30.00% | 24 | 2 |
| Dec 31, 2022 | 20 | 11 | 122.22% | 17 | 3 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Valneva SE | 674 |
| Arvinas | 246 |
| CorMedix | 191 |
| Prime Medicine | 146 |
| Verastem | 102 |
| OmniAb | 89 |
| Altimmune | 57 |
SPRY News
- 3 days ago - Kaplan Fox Urges Investors of ARS Pharmaceuticals Inc. (SPRY) with Significant Losses to Seek a Leadership Role Before October 5, 2026 - Newsfile Corp
- 4 days ago - ARS Pharmaceuticals reports Q2 EPS (63c), consensus (49c) - TheFly
- 4 days ago - ARS Pharmaceuticals sees cash flow break-even by end of 2027 - TheFly
- 4 days ago - ARS Pharmaceuticals names Meg Smith as Chief Commercial Officer - TheFly
- 6 days ago - Kaplan Fox Reminds ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery of the Lead Plaintiff Deadline on October 5, 2026 - Newsfile Corp
- 6 days ago - ARS Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 6 days ago - ARS Pharmaceuticals Earnings release: Q2 2026 - Filings
- 6 days ago - ARS Pharmaceuticals Quarterly report: Q2 2026 - Filings